Agilent launches new SureGuide CRISPR activation and … – ZenopaZenopaAgilent Technologies has introduced new pooled libraries for CRISPR activation and interference to its SureGuide range.Agilent Expands SureGuide Portfolio with CRISPR-based Products… Continue reading
LowvelderWhat is a stem cell transplant?LowvelderAn example of when stem cells are activated is when you cut yourself or graze your knee. Blood clots form to stop the bleeding. Stem cells get to work to close the wound. They have the potential to diffe… Continue reading
Quad Technologies Patents Novel T-Cell Activation Reagent for Car-T Cell ManufacturingBusiness Wire (press release)WOBURN, Mass.–(BUSINESS WIRE)–Quad Technologies, a leader in cell and gene therapy bioprocessing reagents, announced today the U.S. Pat… Continue reading
Mesothelioma & Asbestos Awareness Center (blog)The Potential of Immunotherapy with Chemotherapy or Radiation for MesotheliomaMesothelioma & Asbestos Awareness Center (blog)Chemotherapy, surgery and radiation have been the standard tools for treating al… Continue reading
Mesothelioma & Asbestos Awareness Center (blog)The Potential of Immunotherapy with Chemotherapy or Radiation for MesotheliomaMesothelioma & Asbestos Awareness Center (blog)Chemotherapy, surgery and radiation have been the standard tools for treating al… Continue reading
BioPharma-Reporter.com |
FDA panel recommends Luxturna gene therapy
AOP Diopsys advert A gene therapy for the treatment of the inherited eye disease, Leber congenital amaurosis (LCA), is a step closer to approval by the US Food and Drug Administration (FDA). The FDA’s Cellular, Tissue and Gene Therapies Advisory Committee … ‘Luxturna’ recommendation good for all AAV based gene therapies says advocacy groupBioPharma-Reporter.com |
BioPharma-Reporter.com |
FDA panel recommends Luxturna gene therapy
AOP Diopsys advert A gene therapy for the treatment of the inherited eye disease, Leber congenital amaurosis (LCA), is a step closer to approval by the US Food and Drug Administration (FDA). The FDA’s Cellular, Tissue and Gene Therapies Advisory Committee … ‘Luxturna’ recommendation good for all AAV based gene therapies says advocacy groupBioPharma-Reporter.com |